![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C34H38N8O12 |
Molar mass | 750.722 g·mol−1 |
3D model ( JSmol) | |
| |
|
HOPO 14-1 is an investigational drug product for removing radioactive contaminants from the body. It is an oral capsule designed to act as a defence against radioactive threats such as nuclear power plant accidents or dirty bomb attacks. [1] [2] The active ingredient is the hydroxypyridinone ligand 3,4,3-LI(1,2-HOPO), which is a powerful chelating agent. [1] [3] HOPO 14-1 works by selectively binding to heavy metals in the body and forming a complex that the body can naturally excrete. [4] The drug is also being studied as a treatment for other forms of heavy metal toxicity, including lead poisoning and exposure to gadolinium from MRI contrast agents. [5] [6] [7] [8] HOPO 14-1 was developed at Lawrence Berkeley National Laboratory by actinide chemist Rebecca Abergel. Abergel and former postdoc Julian Avery Rees co-founded HOPO Therapeutics, a company commercializing HOPO 14-1 and other treatments for heavy metal poisoning.
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C34H38N8O12 |
Molar mass | 750.722 g·mol−1 |
3D model ( JSmol) | |
| |
|
HOPO 14-1 is an investigational drug product for removing radioactive contaminants from the body. It is an oral capsule designed to act as a defence against radioactive threats such as nuclear power plant accidents or dirty bomb attacks. [1] [2] The active ingredient is the hydroxypyridinone ligand 3,4,3-LI(1,2-HOPO), which is a powerful chelating agent. [1] [3] HOPO 14-1 works by selectively binding to heavy metals in the body and forming a complex that the body can naturally excrete. [4] The drug is also being studied as a treatment for other forms of heavy metal toxicity, including lead poisoning and exposure to gadolinium from MRI contrast agents. [5] [6] [7] [8] HOPO 14-1 was developed at Lawrence Berkeley National Laboratory by actinide chemist Rebecca Abergel. Abergel and former postdoc Julian Avery Rees co-founded HOPO Therapeutics, a company commercializing HOPO 14-1 and other treatments for heavy metal poisoning.